The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.
Phase of Trial: Phase 0
Latest Information Update: 24 Aug 2015
Price : $35 *
At a glance
- Drugs Cilostazol (Primary)
- Indications Migraine with aura; Stroke
- Focus Therapeutic Use
- 20 Aug 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 07 Oct 2014 New trial record